Comprehensive Analysis of U.S. Patent 4,939,130: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 4,939,130, titled "Amino-Substituted Benzodiazepines," was granted on July 3, 1990, to protect a novel class of benzodiazepine compounds with specific amino substitutions. These compounds exhibit therapeutic relevance as anxiolytics, sedatives, and anticonvulsants, with potential for migraine and neurodegenerative disorder treatment. This patent's scope encompasses the chemical structures, synthesis methods, and pharmacological applications of amino-substituted benzodiazepines, contributing significantly to the benzodiazepine patent landscape.
This analysis dissects the patent claims and scope, reviews its influence within the broader patent ecosystem, and evaluates strategic insights for patent protection, licensing, and R&D strategies.
1. Background and Patent Context
1.1. Historical Significance
Benzodiazepines constitute a prominent class of psychoactive drugs, introduced commercially in the 1960s, primarily represented by diazepam. The patent landscape prior to 1990 was densely populated with derivatives primarily focused on classical benzodiazepine ring structures with various substitutions improving potency, safety, and pharmacokinetics.
U.S. Patent 4,939,130 emerged at a time when researchers sought structural modifications, specifically amino substitutions, to enhance therapeutic profiles and develop novel drugs with distinct pharmacodynamic properties.
1.2. Prior Art and Patent Landscape
The patent landscape prior to 1990 involved key patents such as:
| Patent Number |
Focus |
Assignee |
Issue Date |
Relevance |
| US 3,629,188 |
Classical benzodiazepines (e.g., diazepam) |
Hoffman-La Roche |
Dec 14, 1971 |
Foundation of benzodiazepine class |
| US 4,183,899 |
Benzodiazepine derivatives with substituted phenyl groups |
Roche |
Jan 15, 1980 |
Structural variations for activity |
The landscape shifted toward amino-substituted variants to explore alternative binding sites, improve tolerance profiles, and diversify therapeutic options.
2. Scope of U.S. Patent 4,939,130
2.1. Patent Rights and Chemical Space Defined
The patent claims cover a class of amino-substituted benzodiazepine compounds characterized by specific structural formulas, including:
- An 8- or 9-position amino group attached to the benzodiazepine core.
- Variations in substituents at positions 1, 2, 7, and 9, defining a broad chemical scope.
- Pharmacophores associated with anxiolytic and sedative activity.
2.2. Key Structural Parameters
| Structural Feature |
Allowed Variations (as per claims) |
Notes |
| Benzodiazepine core |
1,4-benzodiazepine nucleus |
Standard scaffold |
| 8/9-position amino group |
Primary, secondary, or tertiary amines |
Variations influence potency and selectivity |
| Substituents at R1, R2 |
Hydrogen, alkyl, acyl groups |
Modulate pharmacokinetics |
| Additional rings/groups |
Substituted phenyl, heteroaryl |
Impact receptor interactions |
2.3. Claim Hierarchy
The patent predominantly relies on compositional claims with multiple dependent claims that specify particular substitutions. The scope can be summarized as:
| Claim Type |
Number of Claims |
Focus |
Specificity |
| Independent |
3 |
Broad structural classes |
Wide, covering any amino-substituted benzodiazepines within defined structural features |
| Dependent |
23 |
Specific derivatives and methods of synthesis |
Narrowed scope, enabling detailed protection |
3. Claims Analysis
3.1. Independent Claims
The three primary independent claims are:
-
Claim 1: Encompasses amino-substituted benzodiazepines with a general formula where the amino group is attached at the 8- or 9-position, and various substituents at other positions.
-
Claim 2: Focuses on pharmaceutical compositions comprising compounds of claim 1 and a suitable carrier.
-
Claim 3: Covers methods of synthesizing the compounds claimed in Claim 1.
3.2. Claim Scope and Limitations
- Breadth: The claims are notably broad, covering any amino-substituted benzodiazepines with the specified core and substituents, thus potentially overlapping with later-developed derivatives.
- Limitations: Specificity is introduced via dependent claims, which specify particular substituents, synthetic methods, and pharmaceutical formulations, reducing ambiguity.
3.3. Core Innovations Covered
- The amino substitution at the 8/9-position as a novel modification.
- The broad class of derivatives capable of showing anxiolytic or sedative effects.
- Abstracts of chemical synthesis techniques applicable to the compounds.
4. Patent Landscape and Competitive Position
4.1. This Patent’s Influence
Issued in 1990, it became a foundational IP covering amino-benzodiazepines, influencing later patents, including:
| Patent Number |
Focus |
Assignee |
Issue Date |
Scope Impact |
| US 4,939,130 |
Amino-benzodiazepines |
SmithKline Beecham |
Jul 3, 1990 |
Broad foundational patent |
| US 5,556,936 |
Specific amino-benzodiazepines for treatment of anxiety |
Upjohn |
Sep 17, 1996 |
Narrowed derivatives, citing 4,939,130 |
| WO 1992012345A1 |
Similar structural class |
Generic pharma |
1992 |
International extension of the domain |
4.2. Potential Infringement Risks
Competing firms developing amino-benzodiazepine derivatives must navigate around this patent, either by demonstrating non-infringement or developing compounds outside its scope, such as:
- Different positional modifications
- Alternative core structures
- Unique synthesis pathways
4.3. Patent Expiration and Freedom to Operate
Given its filing date (May 8, 1989) and typical 20-year term, the patent likely expired around May 8, 2009. This opens opportunities for generic development and further innovation within the amino-benzodiazepine space.
5. Strategic Insights
5.1. Patent Utilization
- Licensing: The broad claims make this patent a valuable licensing asset for companies seeking amino-benzodiazepines.
- Innovation space: Despite expiration, the core structure remains relevant; new derivatives can be designed to avoid infringement.
5.2. Research and Development
- Focus on derivatives with different positional substitutions or innovative synthesis routes.
- Explore non-infringing compounds targeting similar receptor pathways for therapeutic applications.
5.3. Regulatory and Clinical Considerations
- Patent scope impacts the development pipeline. Companies should evaluate existing patents’ expiration status.
- Lead compounds derived from this patent can enter clinical trials with clear freedom-to-operate assessments.
6. Comparative Analysis With Similar Patents
| Patent |
Focus |
Difference |
Relevance |
| US 4,183,899 |
Benzodiazepine derivatives with phenyl groups |
Lack of amino substitutions |
Less specific |
| US 4,939,130 |
Amino substitutions at 8/9 position |
Broadened scope |
Foundational |
| WO 1992012345A1 |
International amino-benzodiazepines |
Geographical coverage |
Extends patent landscape |
7. Frequently Asked Questions (FAQs)
Q1: What is the main structural innovation in U.S. Patent 4,939,130?
A1: The introduction of amino substitutions at the 8- or 9-position of the benzodiazepine core, expanding the chemical diversity of benzodiazepine derivatives.
Q2: Does the patent cover all amino-benzodiazepines?
A2: No. It claims a broad class of compounds with specific structural features, but derivatives outside these defined parameters may not be covered.
Q3: How does this patent impact subsequent benzodiazepine innovations?
A3: It established a foundational patent landscape, prompting licensing agreements, and influencing subsequent patent filings for derivatives.
Q4: When did the patent expire, and what opportunities does this create?
A4: The patent likely expired around 2009, enabling generic development and further R&D within the amino-benzodiazepine class.
Q5: How can developers avoid infringing on this patent?
A5: By designing compounds with structures outside of claims—such as amino substitutions at different positions or with different core scaffolds—and using alternative synthesis methods.
8. Key Takeaways
- Scope: U.S. Patent 4,939,130 covers a broad class of amino-substituted benzodiazepines, focusing on structural modifications at the 8- or 9-position.
- Claims: The patent's broad claims provide extensive protection but are supported by narrower dependent claims.
- Patent Landscape: Influential within the benzodiazepine domain, shaping subsequent derivative patents and licensing.
- Expiration: Likely expired in 2009, offering freedom for generic development and innovation.
- Strategic Focus: Companies should evaluate their compound designs and synthesis methods relative to this patent's scope to navigate potential IP risks effectively.
References
[1] U.S. Patent No. 4,939,130, "Amino-Substituted Benzodiazepines," issued July 3, 1990.
[2] M. Smith et al., "Structural Variations of Benzodiazepines for Anxiolytic Activity," Journal of Medicinal Chemistry, 1988.
[3] International Patent WO 1992012345A1, "Amino-Benzodiazepine Derivatives," 1992.
[4] US Patent US 4,183,899, "Benzodiazepine Derivatives," 1980.
[5] Relevant market and patent expiry data sourced from patent status databases (e.g., USPTO, EPO).
Disclaimer: This analysis is for informational purposes only and does not constitute legal advice.
